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Atrial fibrillation (AF) significantly increases the risk of stroke and, therefore, stroke
prevention is an essential component of the management for patients with AF. This
requires formal assessment of the individual risk of stroke to determine if the pa-
tient is eligible for oral anticoagulation (OAC), and if so, their risk of bleeding on
OAC, before a treatment decision regarding stroke prevention is made. Risk of stroke
is not homogenous; it depends on the presence or absence of risk factors. A plethora
of stroke and bleeding risk factors has been identified, including common and less-
well established clinical risk factors, plus imaging, urine, and blood biomarkers.
Consequently, there are several stroke and bleeding risk stratification scores avail-
able and this article provides an overview of them, the risk factors included and how
they are scored, and provides a critical appraisal of them. The review also discusses
the debate regarding whether female sex is a risk factor or a risk modifier, and high-
lights the dynamic nature of both stroke and bleeding risk and the need to re-assess
these risks periodically to ensure treatment is optimal to reduce the risk of adverse
outcomes. This review also summarizes the recommended stroke and bleeding risk
stratification scores from all current major international guidelines.
Introduction
Atrial fibrillation (AF) increases the risk of stroke five-fold
independently of other risk factors1 and, therefore, the pri-
mary focus for the management of patients with AF is
stroke prevention with oral anticoagulation.2–8 Major clini-
cal guidelines advocate an integrated approach to theman-
agement of AF patients, with contemporary guidelines,6,8
recommending the Atrial Fibrillation Better Care (ABC)
pathway9 (Figure 1).
The ‘A’ criterion represents ‘Avoiding stroke with
Anticoagulation’ and outlines three steps in the decision-
making process. Firstly, to identify patients at low risk who
do not require oral anticoagulation (OAC), with the remain-
der being offered appropriate OAC (Step 2), and the final
step deciding on the choice of OAC.9
Risk of stroke is heterogeneous, dependent on the pres-
ence of risk factors and risk modifiers.6,8 Therefore, the ini-
tial stage requires assessment of the individual patients’ risk
of stroke to identify those who require stroke prevention
therapy, followed by an assessment of their individual risk of
major bleeding on OAC, and an assimilation of the synergis-
tic effect of both stroke and bleeding risk factors to deter-
mine the most appropriate OAC and the correct dose. There
are several stroke and bleeding risk stratification scores
available and the aim of this article is to provide an over-
view and critical appraisal of these and to discuss the evolu-
tion of the concept of risk in this population.
Stroke risk assessment
There are many stroke risk factors and the more common
and validated ones have been used to formulate stroke risk
stratification schema. The first of the popular risk scores
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was the CHADS2,
10 which was a simple clinical score based
on five stroke risk factors from the AF Investigators and the
Stroke Prevention in AF trial, derived and validated in a
registry of hospitalized AF patients. Since then, several
new stroke risk stratification tools have been proposed,
Framingham,11 CHA2DS2-VASc,
12 ATRIA,13 ABC,14 and
GARFIELD-AF,15 with the majority emerging over the last
10 years (Tables 1 and 2). The number of risk factors in-
cluded in these schemas varies considerably, from four in
the ABC-Stroke score14 to eight in the GARFIELD-AF15 and
ATRIA-Stroke13 scores, with all stroke risk scores including
age and previous stroke 6 transient ischaemic attack (TIA)
and/or thromboembolism. Not all risk factors for stroke
confer equal risk; age and previous stroke are
independently associated with a greater risk of stroke; the
CHA2DS2-VASc score acknowledges this increased risk by
awarding each of these risk factors two points. However,
the combination of other risk factors differs between the
risk scores with only the CHA2DS2-VASc, Framingham, and
CHADS2 scores, including routinely available demographic
and clinical variables, while the others13–15 also include
urine (renal function13,15 proteinuria13) and blood14 bio-
markers. Further, the definitions of mutual risk factors dif-
fer between risk scores (Table 1) and the complexity and
ease of calculation also varies markedly (Table 2), with the
latter limiting the clinical applicability of some
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Figure 1 Atrial fibrillation better care pathway. ABC, atrial fibrillation better care; APT, antiplatelet therapy; BP, blood pressure; CHA2DS2-VASc, con-
gestive heart failure, hypertension, age 75 years (2 points), diabetes, stroke/TIA/thromboembolism (2 points), vascular disease, age 65–74 years, sex
category (female); DM, diabetes mellitus; HAS-BLED, (uncontrolled) hypertension, abnormal renal, or liver function, stroke, bleeding, labile interna-
tional normalized ratio, elderly, drugs/drink (alcohol); HF, heart failure; NOAC, non-vitamin K antagonist oral anticoagulant; NSAIDs, non-steroidal anti-
inflammatory drugs; OAC, oral anticoagulation; OSA, obstructive sleep apnoea; TTR, time in the therapeutic range; VKA, vitamin K antagonist. #, re-
duced/decreased. Adapted from Ref.8
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Age threshold
The age cut-off criteria among the stroke risk scores
vary although most10,12–14 use 65 years to indicate
greater risk. Two recent analyses, one in the Korean
National Insurance Service database [n¼ 426 650 OAC-
naı̈ve AF patients with 2 non-sex-related CHA2DS2-
VASc risk factors (CHA2DS2-VASc 0–2 in men and 1–3 in
women)]17 and the other in the Taiwan National
Insurance Research Database [non-anticoagulated AF
patients: 9416 men (CHA2DS2-VASc score of 0) and 6390
women (CHA2DS2-VASc score of 1)],
18 suggest that
among Asian patients a lower age (<65 years) threshold
should be considered to indicate elevated stroke risk.
In the Korean cohort,17 although older age (65–74 or
75 years) was the most important risk factor for
ischaemic stroke, patients aged 55–59 years with no
risk factors had a similar risk of ischaemic stroke when
compared with AF patients with one non-sex-related
risk factor. In the Taiwanese cohort, the annual risk of
stroke was 1.78% among those aged 50–64 years which
exceeds the ‘normal’ treatment threshold to prevent
stroke of 1%, and thus a lower age threshold may be
appropriate in Asian patients with AF. It is important to
investigate if the current convention of age 65 years
remains the appropriate age cut-off to indicate greater
stroke risk in all populations.
Sex—is it a risk modifier or a risk factor for
stroke in AF patients?
There has also been some debate over whether female sex
is a risk factor for stroke or a risk modified.19–24 An analysis
using the Danish nationwide cohort examined the risk of
thromboembolism among men and women with CHA2DS2-
VA score of 0 and demonstrated that female sex was a risk
modifier for stroke in patients with AF rather than a risk
factor20 per se and is dependent on age.19,21,24 In the
Swedish national dataset, womenwith no other risk factors
(CHA2DS2-VASc score of 1) had a low stroke risk, similar to
men with a CHA2DS2-VASc score of 0.
25 Although utilizing
the simplified ‘CHA2DS2-VA score’ could potentially help to
aid the initial decision about OAC in AF patients, ignoring
the sex component completely would undervalue the risk
of stroke among women with AF.19,21 Women have a higher
risk of stroke per se than their male peers, therefore to dis-
regard this, places female patients at risk and could lead to
deleterious outcomes; women stand to gain the greatest
benefit in terms of the largest absolute reduction in stroke.
Also, women with AF tend to under-treated with oral anti-
coagulation; hence ignoring the female sex criterion with
an (as yet non-validated) CHA2DS2-VA score could poten-
tially lead to under-recognition of female sex as a factor
that may affect stroke risk and further increase the sex dif-
ferences in OAC prescribing.26 Women with AF with >1
Table 3 Stroke risk factors in patients with atrial fibrillation
Most common clinical risk factors59 Other clinical risk factors60
Stroke/TIA/thromboembolism Impaired renal function/CKD
Hypertension Obstructive sleep apnoea
Increasing age Hypertrophic cardiomyopathy
Structural heart disease Smoking
Diabetes mellitus Malignancy
Vascular disease Metabolic syndrome (ref 333)
Congestive heart failure/LV dysfunction Hyperlipidaemia
Sex category (female) Amyloidosis in degenerative cerebral and heart diseases
Imaging biomarkers27–29 Blood/urine biomarkers30–33
Echocardiography Cardiac troponin Tand I
LA dilatation Natriuretic peptides
Spontaneous contrast or thrombus in LA Cystatin C
Low LAA velocities Proteinuria
Complex aortic plaque CrCl/ eGFR
CRP
Cerebral imaging IL-6




CKD, chronic kidney disease; CrCl, creatinine clearance; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GDF-15, growth dif-
ferentiation factor-15; IL-6, interlukin-6; LA, left atrial; LAA, left atrial appendage; LV, left ventricular; TIA, transient ischaemic attack.
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non-sex stroke risk factor, have a consistently significantly
higher stroke risk thanmen.20,23
Table 3 summarizes the multitude of stroke risk factors
which have been shown to increase the risk of stroke in AF
patients, including other clinical risk factors not incorpo-
rated into any of the published tools, such as obstructive
sleep apnoea, amyloidosis, and smoking. In addition, cere-
bral and cardiac imaging fleft atrial function and volume,
left atrial fibrosis, left atrial appendage morphology,22,27–
29 and numerous urine and blood biomarkers30–33 [von
Willebrand factor, growth differentiation factor (GDF)-15,
troponin, etc.] have been associated with increased stroke
risk. Indeed, the biomarker, vWF,34 and renal dysfunction35
have been added to the CHA2DS2-VASc score, with mixed
results. von Willebrand factor added to what was then
called the ‘Birmingham risk score’34 modestly improved
the c-statistic for predicting ischaemic stroke [0.640, 95%
confidence interval (CI) 0.563–0.713 vs. 0.679, 95% CI
0.591–0.756] and vascular events [0.670, 95% CI 0.603–
0.726 vs. 0.716, 95% CI 0.643–0.779] in the Stroke
Prevention in AF (SPAF) III cohort. However, adding chronic
kidney disease (CKD) to the CHA2DS2-VASc score in a
Spanish cohort of 978 AF patients on OAC did not improve
the prediction of stroke or systemic embolism, thrombo-
embolic events or all-causemortality.35
The most recent tool proposed is the GARFIELD-AF,15 a
web-based risk score that allows simultaneous calculation
of stroke/systemic embolism (SE) risk, major bleeding, and
all-cause mortality. This score was derived from prospec-
tively collected data from the GARFIELD-AF registry (March
2010 and July 2015; 35 countries in adults with recently di-
agnosed AF) and includes different risk factors for the cal-
culation of stroke (Table 2) and bleeding (age, vascular
disease, and kidney disease), although the exact scoring of
each risk factor is not published. The GARFIELD-AF tool
demonstrated better predictive value (evidenced by c-sta-
tistics) when compared with the CHA2DS2-VASc score for
predicting stroke/systemic embolism [0.69 (95% CI 0.67–
0.71) vs. 0.64 (0.61–0.66), respectively] and haemorrhagic
stroke/major bleeding using the HAS-BLED score [0.66
(0.62–0.69 vs. 0.64 (0.61–0.68), respectively] among those
on OAC and also among lower risk patients (CHA2DS2-VASc
score 0 or 1 in men and 1 or 2 in women) [0.65, 0.56–0.73
vs. 0.59, 0.50–0.67; for stroke/SE and 0.60, 0.47–0.73 vs.
0.55, 0.53–0.56; for haemorrhagic stroke/major bleed-
ing].15 The GARFIELD-AF tool is advantageous in that is
offers simultaneous calculation of stroke/SE, major bleed-
ing and all-cause mortality risk, but it requires a computer
or smartphone to enable calculation thus limiting it clinical
utility, and it offers only modest but statistically significant
improvement in the c-statistics compared to the simple
(able to be calculated at the bedside frommemory) scores,
such as the CHA2DS2-VASc and HAS-BLED scores. Indeed, a
recent European Heart Rhythm Association and Young
Electrophysiologist survey on the utility of the CHA2DS2-
VASc score demonstrated that most physicians calculated
the CHA2DS2-VASc score frommemory.
36
Combining the CHA2DS2-VASc score with the
Intermountain Mortality Risk Score (IMRS),37 which consists
of age, sex, complete blood count (CBC), and basic meta-
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and BMP) improved the prediction of stroke (and mortal-
ity), in a cohort of 10 077 AF patients undergoing AF cardiac
catheterization37; a four-fold separation between low and
high risk in those with a CHA2DS2-VASc score of 2.
The purpose of a risk assessment tool is to be reduction-
ist, to simplify the information required to identify an ‘at
high-risk group’ and to aid treatment decision making.
They are necessarily an over-simplification. All clinical risk
scores have at best, modest predictive power to identify
those at risk of the outcome of interest; the CHA2DS2-VASc
score and other stroke and bleeding risk scores are no
exceptions. The addition of more clinical factors may lead
to slight improvements in the overall predictive accuracy
of the score, evidenced by an improvement in the c-statis-
tic, but this statistically significant increase may not trans-
late into a meaningful clinical difference, especially in
real-world cohorts.38,39 Supplementing extra biomarkers
into risk scores slightly increases the prognostic ability of
risk scores over and above clinical risk factors alone but in
the majority of patients is unlikely to change the funda-
mental decision regarding whether or not to prescribe anti-
coagulation, yet adds to the complexity and reduces
clinical utility.27 Also many biomarkers are non-specific,
and abnormal levels are likely to reflect a ‘sicker’ patient
or concomitant comorbidities.40
A meta-analysis of studies comparing just the CHA2DS2-
VASc and ATRIA stroke scores demonstrated that the ATRIA-
stroke score performed better for stroke risk prediction
but that the CHA2DS2-VASc was superior to ATRIA for identi-
fying truly low-risk patients.41 A Patient Centred Outcomes
Research Institute (PCORI) systematic review42 evaluated
the prognostic precision of CHA2DS2-VASc, CHADS2
Framingham, and ABC stroke risk stratification tools, iden-
tifying 61 studies, and assessed the strength of evidence.
This independent review demonstrated that CHA2DS2-
VASc, CHADS2, and the ABC-stroke scores had the best pre-
dictive ability (based on the c-statistic) for stroke.
Consequently, the most commonly utilized stroke risk score
is the CHA2DS2-VASc score and is recommended by all the
major international clinical guidelines for assessing stroke
risk in AF patients (Tables 4 and 5).
Benefits/limitations of adding biomarkers to
risk stratification scores
As alluded to previously, incorporating imaging, urine, and
blood biomarkers into risk stratification scores can improve
their predictive ability, but the incremental benefit over a
clinical risk factor-based score is often negligible.
Biomarkers increases healthcare costs, can delay treat-
ment decisions, and may lead to inequitable care due to
their availability. Some biomarkers, such as cardiac tropo-
nins (T and I), NT-proBNP, D-dimer, and eGFR, are readily
available in clinical practice, whereas many of the others
are not (IL-6, GDF-15, and vWF), and there may be intra-
and inter-assay variation. Biomarkers are non-specific and
tend to predict increased risk per se (hospitalization,
death, stroke, etc.) and therefore they may simply be
markers of ‘sicker’ patients. We do not currently have con-
temporary data on the risk of stroke associated with bio-
markers among non-anticoagulated patients with AF nor
unequivocal evidence that OAC is advantageous/favour-
able in patients designated as ‘low-risk’ based on bio-
marker(s) risk factors. The patient pathway would include
newly diagnosed and often non-anticoagulated patients
whomay or may not be on aspirin; a biomarker-based score
would need to show data in these groups to aid decision-
making in all steps of the AF patient journey. In addition,
the current complex algorithms/nonograms required to
compute some risk scores,14,15,43,44 particularly those in-
corporating biomarkers, severely limits their use in routine
clinical practice. Greater widespread implementation of
electronic health records may permit automated calcula-
tion of stroke and bleeding risk in AF patients using any
pre-programmed risk scores, thereby negating their com-
plexity and permitting greater clinical application.
However, eliminating the need for the physician/health-
care professional to complete the risk assessment them-
selves by providing an automated score, removes the
opportunity to consider the individual risk factors, many of
which may need to be addressed and managed (blood pres-
sure, heart failure, diabetes, etc.) in order to reduce risk.
Table 5 Summary of stroke and bleeding risk scores recommended for use in current major international guidelines for the man-
agement of AF
Clinical guideline for AF management Recommended stroke risk score Recommended bleeding risk score
2020 European Society of Cardiology6 CHA2DS2-VASc HAS-BLED
2019 AHA/ACC/HRS7 CHA2DS2-VASc No specific risk score specified
2018 American College of Chest Physicians8 CHA2DS2-VASc HAS-BLED
2018 Cardiac Society of Australia and New
Zealand3
CHA2DS2-VA(Sc) No specific risk score specified
2017 Asia Pacific Heart Rhythm Society5 CHA2DS2-VASc HAS-BLED
2015 Canadian Cardiovascular Society4 CHA2DS2-VA No specific risk score specified
2014 National Institute of Clinical Excellence2 CHA2DS2-VASc HAS-BLED
ACC, American College of Cardiology; AHA, American Heart Association; CHA2DS2-VASc, congestive heart failure, hypertension, age 75 years (2
points), diabetes, stroke/TIA/thromboembolism (2 points), vascular disease, age 65–74 years, sex category (female); HAS-BLED, (uncontrolled) hy-
pertension, abnormal renal or liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs/drink (alcohol); HRS, Heart
Rhythm Society.
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There may be a role for biomarkers in differentiating low
risk and those with 1 (non-sex) risk factors,45 however, the
basic premise of stroke risk stratification is to determine if
someone requires OAC or not; this can be simply, quickly,
and reliably done without adding biomarkers. Therefore,
biomarkers currently have limited clinical application for
stroke risk assessment but could be utilized to refine or
personalize risk assessment in selected patients.
Limitations of clinical risk scores
One of the major problems with assessing risk related to
stroke prevention in AF patients is that there is consider-
able overlap between risk factors for stroke and risk factors
for bleeding, namely age, previous stroke, uncontrolled hy-
pertension, renal dysfunction, etc. The cohorts from which
the stroke and bleeding risk scores were derived varied
considerably, prospective registries, or cohorts,11–13,15,46–48
non-vitamin K antagonist oral anticoagulant (NOAC) clini-
cal trials,14,43 and retrospective cohorts,10,44,49 with not all
risk factors recorded, missing data, and in some studies,
stroke and bleeding outcome events were not adjudicated,
and this may have led to under- or over-reporting.
Subsequent validations of stroke and bleeding risk scores
have also been conducted in a variety of cohorts, mainly
retrospective cohort studies or registries in a range of set-
tings (in-hospital vs. community), with significant demo-
graphic and clinical heterogeneity in terms of age,
ethnicity, geographical region, clinical risk factors, propor-
tion receiving OAC, outcome(s) verification, etc. and
methodological variation with the inclusion or exclusion of
those subsequently receiving OAC affecting event rates.
Bleeding risk assessment
Amultitude of risk factors that increase the risk of bleeding
in patients with AF have been identified (Table 6), some
are modifiable (blood pressure, adherence to OAC, etc.) or
potentially modifiable (falls risk, anaemia, etc.), while
others, such as age and clinical history, are fixed. Different
combinations of these risk factors have been incorporated
into risk scores and there are currently six-validated risk
scores available for the assessment of bleeding in patients
with AF (Tables 6 and 7): HAS-BLED,46 ATRIA,47 ABC,43
ORBIT,48 HEMORR2HAGES,
49 and Shireman.44 As shown in
Table 6, the number of risk factors within each score is vari-
able, ranging from 12 in HEMORR2HAGES
49 to 3 in the ABC-
bleeding score,43 with inconsistency in the definitions of
risk factors. All the scores include age and previous bleed-
ing history/bleeding predisposition, although the age
threshold for increased risk varies, with ABC-Bleeding43 us-
ing a cut-off of 50years and older, compared to 65 for
HAS-BLED, 70 for Shireman,44 and 75 years49 and
older47,48 for the others. With regard to bleeding, some in-
clude any previous bleeding history,43,44,47,49 HAS-BLED46
incorporates previous major haemorrhage only, while
ORBIT48 combines gastrointestinal and intracranial bleeds
and haemorrhagic stroke. Further, some scores also assess
separately factors, such as anaemia44,46–49 and reduced
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predisposition (i.e. anaemia or severe thrombocytopenia)
together with previous major bleeding. Renal dysfunc-
tion,46–49 (uncontrolled)46,49 hypertension,47 concomitant
APT,44,46,48 and alcohol excess44,46,49 were included in at
least half of the scores. Risk factors, such as hepatic dis-
ease,46,49 female sex,44 diabetes,44 cancer,49 labile
International Normalised Ratio (INR),46 excessive falls
risk,49 biomarkers,43 and genetic factors49 feature infre-
quently in the bleeding risk scores.
As seen with stroke risk scores, the bleeding risk
scores also vary considerably in their complexity, ease of
computation, and routine availability of each risk factor
and the same associated limitations apply to bleeding
risk scores as discussed earlier in relation to stroke risk
scores.
A systematic review and meta-analysis50 compared the
sensitivity, specificity, and diagnostic odds ratio of HAS-
BLED to ATRIA (four studies) and HEMORR2HAGES (five
Table 7 Risk stratification scores for assessing bleeding risk in patients with atrial fibrillation and bleeding events in the validation
cohorts
Risk score Risk factors (score for each
factor)
Risk categories Bleeding events in validation cohort
(per 100 patient years)
Low Intermediate High Low Intermediate High
ABC †,43 Age(†); biomarkers (†) (GDF-
15 or cystatin C/CKD-EPI,
cTnT-hs, & Hb); Previous
bleed (†)
<1% 1–2% >3% 0.62 1.67 4.87
ATRIA47 Anaemia (3); severe renal
disease (3); Age 75 (2);
prior bleed (1); hyperten-
sion (1)
0–3 4 5–10 0.83 2.41 5.32
HAS-BLED46 "SBP (1); severe renal/he-
patic disease (1 each);
stroke (1); bleeding his-
tory or predisposition (1);
labile INR (1); Age >65
(1); APT/NSAIDs (1); alco-
hol excess (1)
0–1 2 3 1.02–1.13 1.88 3.74
HEMORR2HAGES
49 Hepatic/renal disease (1);
ethanol abuse (1); malig-
nancy (1); age >75 (1);
#Plt (1); re-bleeding risk
(2); "BP (1); anaemia (1);
genetic factors (1); " falls
risk (1); stroke (1)
0–1 2–3 4 1.9–2.5 5.3–8.4 10.4–12.3
ORBIT48 Age 75 (1); #Hb/Hct/anae-
mia (2); Bleeding history
(2); # renal function (1);
APT (1)
0–2 3 4 2.4* 4.7 8.1







1.07 >1.07/ <2.19 2.19 0.9% a 2.0% a 5.4% a
Taken from Refs.8,61
ABC, Age, biomarkers, clinical history; APT, antiplatelet therapy; ATRIA, Anticoagulation and Risk Factors in Atrial fibrillation; BP, blood pressure;
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; cTnT-hs, high-sensitivity cardiac troponin T; GDF-15¼ growth differentiation factor-15;
HAS-BLED, (uncontrolled) hypertension, abnormal renal or liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs/drink
(alcohol); HEMORR2HAGES, Hepatic/renal disease, ethanol abuse, malignancy, age, reduced platelet function, re-bleeding risk [2 points], (uncon-
trolled) hypertension, anaemia, genetic factors, falls risk, stroke; Hb, haemoglobin; Hct, haematocrit; HAS-BLED, (uncontrolled) hypertension, ab-
normal renal or liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs/drink (alcohol); HEMORR2HAGES, Hepatic/renal
disease, ethanol abuse, malignancy, age, reduced platelet function, re-bleeding risk [2 points], (uncontrolled) hypertension, anaemia, genetic fac-
tors, falls risk, stroke; INR, international normalized ratio; NSAIDs, non-steroidal anti-inflammatory drugs; ORBIT-AF, Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation; Plt, platelet count or function; SBP, systolic blood pressure.
*Bleeding event in original derivation cohort;
aAt 3months; # reduced/decreased; " elevated/increased;
†Score for each variable in ABC score is based on a nonogram (see Ref.4).
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studies). HAS-BLED was more sensitive in predicting major
bleeding than ATRIA [0.53 (0.52–0.54) vs. 0.27 (0.26–0.27),
respectively] or HEMORR2HAGES [0.41 (0.35–0.48) vs. 0.23
(0.17–0.29), respectively]. Another systematic review and
meta-analysis51 compared the predictive ability of HAS-
BLED to assess risk of major bleeding on OAC in patients
with AF to HEMORR2HAGES, ATRIA (with 11 studies compar-
ing the 3 bleeding risk scores), CHADS2, and CHA2DS2-VASc.
All three bleeding risk scores had similar predictive ability
[pooled c-statistics (95% CI) for HAS-BLED 0.65 (0.61–0.69),
HEMORR2HAGES 0.63 (0.61–0.66) and ATRIA 0.63 (0.56–
0.72)] in predictingmajor bleeding. Based on net reclassifi-
cation improvement and integrated discrimination im-
provement analyses, the HAS-BLED score was superior in
predicting major bleeding risk compared to
HEMORR2HAGES and ATRIA.
51 More recently a PCORI sys-
tematic review42 identified 38 studies relating to bleeding
risk in AF which compared HEMORR2HAGES, HAS-BLED,
ATRIA, ABC-Bleeding, and concluded that the HAS-BLED
score was the best risk score for predicting major bleeding
but with amodest strength of evidence.42
The purpose of the assessing bleeding risk on OAC is to
identify patients at high risk of bleeding, who may require
more intensive follow-up and those with modifiable bleed-
ing risk factors (Figure 1 and Table 8) which can be
addressed to remove or reduce the risk to the patient (con-
trolling blood pressure, cessation of non-essential APT/
NSAIDs, improving INR control if patient is receiving a vita-
min K antagonist, and reduction/cessation of alcohol in-
take; Figure 1). Assessing bleeding risk on OAC treatment
permits frank discussion with the patient about their indi-
vidual treatment benefit/risk, allows the patient to make
a more informed decision about treatment, and discussion
of the patient’s role in reducing their risk of harm and
highlighting signs and symptoms of bleeding and appropri-
ate management. An analysis has shown that utilizing a val-
idated bleeding risk score to assess bleeding risk in AF
patients is preferable to reliance on assessment using mod-
ifiable bleeding risk factors alone.52 In a prospective
cluster-randomized trial, appropriate use of the HAS-BLED
score as part of structured care, based on the ABC pathway,
to address and mitigate modifiable bleeding risks, and
scheduling follow-ups, was associated with lower bleeding
rates and an increase in OAC use when compared with
‘usual care’ managed patients.53
Dynamic nature of risk
Risk of stroke and bleeding are on a continuum and change
temporally, with age being the biggest driver of risk, to-
gether with the accumulation of new risk factors over the
life course, and treatment, affecting overall risk. However,
often risk of stroke and bleeding is undertaken when the
patient is first diagnosed and/or anticoagulation is initi-
ated, whereas the dynamic nature of risk necessitates peri-
odic re-assessment of both stroke and bleeding risk factors
to ensure treatment is appropriate. This is important for all
patients with AF, particularly for those initially considered
‘low-risk’ who may not be receiving OAC, but who will re-
quire it once they reach the requisite age threshold, or as
Table 8 Risk factors for bleeding with oral anticoagulation or antiplatelet therapy
Modifiable Potentially modifiable
Hypertension/elevated SBP Anaemia
Concomitant antiplatelet/NSAID Severe frailty 6 excessive risk of falls
Excessive alcohol intake Reduced platelet count or function
Non-adherence to OAC Renal impairment with CrCl <60 mL/min
Hazardous hobbies/occupations VKA management strategy
Bridging therapy with heparin
INR control (target 2.0–3.0), target TTR >70%
Appropriate choice of OAC and correct dosing
Non-modifiable Biomarkers
Age >65 years GDF-15
Previous major bleeding Cystatin C/CKD-EPI/ cTnT-hs
Severe renal impairment (on dialysis or renal transplant) von Willebrand factor (and other coagulation
markers)
Severe hepatic dysfunction (cirrhosis)
Malignancy
Genetic factors (e.g. CYP 2C9 polymorphisms)




CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CrCl, creatinine clearance; cTnT-hs, high-sensitivity cardiac troponin T; CYP 2C9, cy-
tochrome P450 2C9; GDF-15, growth differentiation factor-15; INR, international normalized ratio; NSAID, non-steroidal anti-inflammatory drugs;
OAC, oral anticoagulation; SBP, systolic blood pressure; TTR, time in the therapeutic range.
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they develop new risk factors. Re-assessment of stroke and
bleeding risk factors is also important to ensure that treat-
ment is appropriate, particularly factors that might affect
OAC safety (age, renal function, cognitive impairment,
uncontrolled hypertension, medication adherence/poor
time in the therapeutic range, drug interactions, concomi-
tant antiplatelet, etc.).
Recently several studies have examined the dynamic na-
ture of stroke and bleeding risk factors in AF patients,54 al-
though to date most were conducted in Asian populations
(Taiwan and South Korea).55–57 Two56,57 studies have exam-
ined the dynamic change in CHA2DS2-VASc score over time.
Chao et al.56 utilized the Taiwanese National Health
Insurance Research Database cohort of 31 039 AF patients
whose only risk CHA2DS2-VASc stroke risk factors were their
age and/or sex, who were not receiving antithrombotic
therapy at baseline. During follow-up, 64.4% patients de-
veloped 1 new comorbidities; the mean change in
CHA2DS2-VASc score was 1.02 (1.29–2.31). Those who suf-
fered an ischaemic stroke were significantly more likely to
have a change in their CHA2DS2-VASc score of1 compared
to those without ischaemic stroke (89.4% vs. 54.6%, respec-
tively). Change in the CHA2DS2-VASc score predicted inci-
dent ischaemic stroke better than baseline or follow-up
CHA2DS2-VASc score. The analysis of the Korean National
Health Insurance Service database (n¼ 167 262 OAC-naı̈ve
AF patients) followed up over 10 years revealed that 46.6%
and 72.0% of ‘low-risk’ and ‘moderate-risk’, respectively,
were re-classified to a high stroke-risk group. The change
in CHA2DS2-VASc score and follow-up CHA2DS2-VASc score
were better predictors of incident ischaemic stroke than
baseline CHA2DS2-VASc score.
57 Similar observations were
evident from a European cohort.58
The dynamic change in HAS-BLED score was also exam-
ined in a subgroup of the Taiwanese national cohort, among
19 566 AF patients receiving warfarin who had a baseline
HAS-BLED score2.55 HAS-BLED score remained unchanged
in 38.2% during a follow-up of 93 783 person-years. Among
those experiencing a major bleed, significantly more had a
change in their HAS-BLED score of 1 or more compared to
those who did not have a major bleed (76.6% vs. 59.0%, re-
spectively). Change in HAS-BLED score or follow-up HAS-
BLED score was a better predictor of major bleeding than
baseline HAS-BLED score.
These studies support the need to re-assess stroke and
bleeding risk to ensure OAC treatment is appropriate and car-
diovascular and other comorbidities are correctly managed to
reduce the risk of ischaemic stroke and major bleeding and
other adverse outcomes (death and hospitalization).
Conclusions
There are several validated stroke and bleeding risk strati-
fication scores available; major international guidelines
recommend the use of the CHA2DS2-VASc score to assess
stroke risk and formal assessment of bleeding risk, with
most favouring the HAS-BLED score. Biomarkers (cardiac
and cerebral imaging, urine, and blood) can improve the
predictive ability of risk scores but lack of routine availabil-
ity to measure these in clinical practice, limited evidence
on their sensitivity and specificity for stroke and bleeding
in AF patients, and the added difficulty in calculating more
complex risk scores based on nonograms/formulas, limits
their clinical utility. It is important to remember that risk
of stroke and bleeding changes over time and with acquir-
ing more comorbidities, therefore regular reassessment of
risk is essential to ensure appropriate AF management and
to reduce the risk of adverse outcomes.
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